Literature DB >> 33216365

Sex differences in outcomes in multiple myeloma.

Benjamin A Derman1, Spencer S Langerman2, Maya Maric2, Andrzej Jakubowiak1, Wei Zhang3, Brian C-H Chiu2.   

Abstract

Entities:  

Keywords:  gender; multiple myeloma; sex

Year:  2020        PMID： 33216365      PMCID： PMC8182969          DOI： 10.1111/bjh.17237

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

1.  Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

Authors:  Roberto J Pessoa de Magalhães; María-Belén Vidriales; Bruno Paiva; Carlos Fernandez-Gimenez; Ramón García-Sanz; Maria-Victoria Mateos; Norma C Gutierrez; Quentin Lecrevisse; Juan F Blanco; Jose Hernández; Natalia de las Heras; Joaquin Martinez-Lopez; Monica Roig; Elaine Sobral Costa; Enrique M Ocio; Martin Perez-Andres; Angelo Maiolino; Marcio Nucci; Javier De La Rubia; Juan-Jose Lahuerta; Jesús F San-Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  Sex disparities in cancer mortality and survival.

Authors:  Michael B Cook; Katherine A McGlynn; Susan S Devesa; Neal D Freedman; William F Anderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-12       Impact factor: 4.254

3.  Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.

Authors:  Benjamin A Derman; Keriann Kordas; Jean Ridgeway; Selina Chow; William Dale; Sang Mee Lee; Elingel Aguada; Andrzej J Jakubowiak; Jagoda Jasielec; Justin Kline; Satyajit Kosuri; Richard A Larson; Hongtao Liu; Mylove Mortel; Olatoyosi Odenike; Jennifer Pisano; Peter Riedell; Wendy Stock; Michael R Bishop; Andrew S Artz
Journal:  Blood Adv       Date:  2019-11-26

4.  CD4+CD25(hi) regulatory T cells in healthy males and females mediate gender difference in the prevalence of autoimmune diseases.

Authors:  Gul Afshan; Nadeem Afzal; Sadia Qureshi
Journal:  Clin Lab       Date:  2012       Impact factor: 1.138

5.  Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.

Authors:  Ulrich Jäger; Michael Fridrik; Markus Zeitlinger; Daniel Heintel; Georg Hopfinger; Sonja Burgstaller; Christine Mannhalter; Wilhelm Oberaigner; Edit Porpaczy; Cathrin Skrabs; Christine Einberger; Johannes Drach; Markus Raderer; Alexander Gaiger; Monique Putman; Richard Greil
Journal:  Haematologica       Date:  2012-04-17       Impact factor: 9.941

6.  Gender disparities in the tumor genetics and clinical outcome of multiple myeloma.

Authors:  Kevin D Boyd; Fiona M Ross; Laura Chiecchio; GianPaolo Dagrada; Zoe J Konn; William J Tapper; Brian A Walker; Christopher P Wardell; Walter M Gregory; Alex J Szubert; Faith E Davies; Gareth J Morgan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-06-15       Impact factor: 4.254

7.  Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.

Authors:  Karthick Raja Muthu Raja; Lucie Rihova; Lenka Zahradova; Maria Klincova; Miroslav Penka; Roman Hajek
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

8.  The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study.

Authors:  Ashley E Thompson; Yvonne Anisimowicz; Baukje Miedema; William Hogg; Walter P Wodchis; Kris Aubrey-Bassler
Journal:  BMC Fam Pract       Date:  2016-03-31       Impact factor: 2.497

9.  Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.

Authors:  Benjamin A Derman; Yuanyuan Zha; Todd M Zimmerman; Rebecca Malloy; Andrzej Jakubowiak; Michael R Bishop; Justin Kline
Journal:  J Immunother Cancer       Date:  2020-01       Impact factor: 13.751
  9 in total
  2 in total

1.  Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.

Authors:  Benjamin A Derman; Ankit Kansagra; Jeffrey Zonder; Andrew T Stefka; David L Grinblatt; Larry D Anderson; Sandeep Gurbuxani; Sunil Narula; Shayan Rayani; Ajay Major; Andrew Kin; Ken Jiang; Theodore Karrison; Jagoda Jasielec; Andrzej J Jakubowiak
Journal:  JAMA Oncol       Date:  2022-09-01       Impact factor: 33.006

2.  Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial.

Authors:  Sarah Bird; David Cairns; Tom Menzies; Kevin Boyd; Faith Davies; Gordon Cook; Mark Drayson; Walter Gregory; Matthew Jenner; John Jones; Martin Kaiser; Roger Owen; Graham Jackson; Gareth Morgan; Charlotte Pawlyn
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2021-04-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.